ProPhase Labs (PRPH) Competitors $2.14 -0.15 (-6.55%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRPH vs. TNXP, CADL, CNTX, SKYE, BDTX, SGMT, LFVN, ACTU, CKPT, and GALTShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Tonix Pharmaceuticals (TNXP), Candel Therapeutics (CADL), Context Therapeutics (CNTX), Skye Bioscience (SKYE), Black Diamond Therapeutics (BDTX), Sagimet Biosciences (SGMT), LifeVantage (LFVN), Actuate Therapeutics (ACTU), Checkpoint Therapeutics (CKPT), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Tonix Pharmaceuticals Candel Therapeutics Context Therapeutics Skye Bioscience Black Diamond Therapeutics Sagimet Biosciences LifeVantage Actuate Therapeutics Checkpoint Therapeutics Galectin Therapeutics Tonix Pharmaceuticals (NASDAQ:TNXP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Do analysts rate TNXP or PRPH? Tonix Pharmaceuticals currently has a consensus target price of $53.50, suggesting a potential upside of 38,306.32%. ProPhase Labs has a consensus target price of $11.00, suggesting a potential upside of 414.02%. Given Tonix Pharmaceuticals' higher possible upside, research analysts clearly believe Tonix Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, TNXP or PRPH? ProPhase Labs has higher revenue and earnings than Tonix Pharmaceuticals. ProPhase Labs is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$7.77M2.46-$116.66M-$110.970.00ProPhase Labs$44.38M0.92-$16.78M-$1.21-1.77 Does the media favor TNXP or PRPH? In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 1 mentions for ProPhase Labs. Tonix Pharmaceuticals' average media sentiment score of 0.11 beat ProPhase Labs' score of -0.07 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TNXP or PRPH more profitable? ProPhase Labs has a net margin of -146.39% compared to Tonix Pharmaceuticals' net margin of -1,196.11%. ProPhase Labs' return on equity of -54.04% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,196.11% -158.27% -119.36% ProPhase Labs -146.39%-54.04%-28.65% Which has more risk and volatility, TNXP or PRPH? Tonix Pharmaceuticals has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Do institutionals and insiders believe in TNXP or PRPH? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer TNXP or PRPH? Tonix Pharmaceuticals received 226 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 62.16% of users gave Tonix Pharmaceuticals an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34062.16% Underperform Votes20737.84% ProPhase LabsOutperform Votes11450.00% Underperform Votes11450.00% SummaryTonix Pharmaceuticals beats ProPhase Labs on 10 of the 17 factors compared between the two stocks. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.83M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.779.93114.8115.14Price / Sales0.92396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.785.324.665.02Net Income-$16.78M$153.56M$119.06M$225.46M7 Day Performance-10.46%0.13%0.80%0.37%1 Month Performance-10.83%15.23%5.65%3.57%1 Year Performance-52.65%41.14%36.75%29.43% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs3.1036 of 5 stars$2.14-6.6%$11.00+414.0%-51.9%$40.83M$44.38M-1.77130News CoverageTNXPTonix Pharmaceuticals3.6465 of 5 stars$0.14-4.3%$53.50+38,361.5%-99.1%$19.09M$7.77M0.00103News CoverageCADLCandel Therapeutics1.5752 of 5 stars$5.28flat$11.00+108.3%+486.7%$169.38M$120,000.00-3.1260Negative NewsCNTXContext Therapeutics3.0516 of 5 stars$2.21+1.4%$6.25+182.8%+104.5%$165.75MN/A-2.087Short Interest ↓News CoverageSKYESkye Bioscience1.6381 of 5 stars$5.38+2.7%$18.67+247.0%+247.5%$163.23MN/A0.0011Gap UpBDTXBlack Diamond Therapeutics2.2329 of 5 stars$2.88+5.1%$15.50+438.2%+56.6%$162.75MN/A-1.9290Upcoming EarningsShort Interest ↑SGMTSagimet Biosciences2.4691 of 5 stars$5.28+2.5%$24.00+354.5%+50.1%$161.94M$2M0.008Analyst ForecastNews CoverageLFVNLifeVantage3.2054 of 5 stars$12.87+5.3%N/A+72.0%$161.13M$200.16M40.22260Earnings ReportDividend AnnouncementShort Interest ↑News CoverageACTUActuate TherapeuticsN/A$8.20+0.9%N/AN/A$160.15MN/A0.0010News CoverageGap UpCKPTCheckpoint Therapeutics3.4263 of 5 stars$3.49+1.5%$12.00+243.8%+90.8%$157.12M$100,000.00-1.8410Short Interest ↑Gap DownGALTGalectin Therapeutics1.6885 of 5 stars$2.49+0.8%$11.00+341.8%+24.4%$155.08MN/A-3.159Positive News Related Companies and Tools Related Companies TNXP Competitors CADL Competitors CNTX Competitors SKYE Competitors BDTX Competitors SGMT Competitors LFVN Competitors ACTU Competitors CKPT Competitors GALT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
